Cyramza

Cyramza (ramucirumab) is an intravenous medication used to treat certain types of cancer. This targeted therapy is designed to inhibit angiogenesis, the process of new blood vessel formation in tumors.

Cyramza is primarily used in combination with other cancer treatments for advanced or metastatic cancers. It is often prescribed for gastric or gastro-esophageal junction adenocarcinoma, non-small cell lung cancer, and colorectal cancer. The medication works by targeting specific proteins involved in tumor blood vessel growth, potentially slowing cancer progression.

Common effects of Cyramza may include fatigue, hypertension, and diarrhea. Some patients may experience appetite loss, nausea, or stomach pain. These effects can vary widely among individuals and are not exhaustive.

Cyramza should be administered under medical supervision due to its potent nature. Patients with a history of severe hypertension, bleeding disorders, or cardiovascular issues should discuss these conditions with their healthcare provider before starting treatment.

Cyramza may interact with other medications, particularly those that affect blood clotting or blood pressure. It is important to inform your healthcare provider about all medications, including over-the-counter drugs and supplements, before beginning Cyramza therapy.